(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/191054 A1

(51) International Patent Classification:
A61K 31/505 (2006.01) *A61P 35/04* (2006.01)
A61K 45/06 (2006.01) *C07K 16/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/EP2025/056840

(22) International Filing Date:
13 March 2025 (13.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

24163724.8	15 March 2024 (15.03.2024)	EP
24172372.5	25 April 2024 (25.04.2024)	EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **BLAKE, Sophia Maria**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **CUARTAS MAZA, Maria Isabel**; Fundaciò Privada Institut d'Investigaciò, Oncològica de Vall d'Hebron, Natzaret, 115-117, 08035 Barcelona (ES). **ECKMANN, Jan**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **PETTAZZONI, Piergiorgio Francesco Tommaso**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **SEOANE SUÁREZ, Juan**; Fundaciò Privada Institut d'Investigaciò, Oncològica de Vall d'Hebron, Natzaret, 115-117, 08035 Barcelona (ES).

(74) Agent: **JOCHNOWITZ, Dr. Evan**; c/o F. Hoffmann-La Roche AG, Patent Department, Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2025/191054 A1

(54) Title: (S,E)-N-(1-CYCLOPROPYL-3-(METHYLSULFONYL)ALLYL)-2-(1,1-DIFLUOROETHYL)-4-PHENOXYPYRIMIDINE-5- CARBOXAMIDE FOR TREATING CANCER

(57) Abstract: The present disclosure describes methods of using a WRN ATP-Dependent Helicase inhibitor (WRNi)to treat diseases associated with microsatellite instability (MSI-H) and/or to treat a patient suffering from a cancer that has relapsed under a prior immunotherapy (e.g., a checkpoint inhibitor therapy).